Document is current
Any future updates will be listed below
-
Authors
Tomé, Sandra O. https://orcid.org/0000-0001-5253-0730
Tsaka, Grigoria
Ronisz, Alicja
Ospitalieri, Simona
Gawor, Klara
Gomes, Luis Aragão
Otto, Markus
von Arnim, Christine A. F.
Van Damme, Philip
Van Den Bosch, Ludo
Ghebremedhin, Estifanos
Laureyssen, Celeste
Sleegers, Kristel
Vandenberghe, Rik https://orcid.org/0000-0001-6237-2502
Rousseau, Frederic https://orcid.org/0000-0002-9189-7399
Schymkowitz, Joost https://orcid.org/0000-0003-2020-0168
Thal, Dietmar Rudolf https://orcid.org/0000-0002-1036-1075
-
Funding
Funding for this research was provided by:
BrightFocus Foundation (A2022019F)
KU Leuven (PDMT2/21/069, C3/20/057, C3/20/057)
Fonds Wetenschappelijk Onderzoek (G0F8516N, G065721N, G065721N)
Vlaamse Impulsfinanciering voor Netwerken voor Dementie-onderzoek (IWT 135043)
Vlaamse Impulsfinanciering voor Netwerken voor Dementie-onderzoek (IWT 135043)
Alzheimer's Association (22-AAIIA-963171)
Mady Browaeys fonds voor Onderzoek naar Frontotemporale Degeneratie
National Institute on Aging (R01AG079234, R01AG079234, R01AG079234)
Internationale Stichting Alzheimer Onderzoek (SAO‐FRA 2019/0015)
Vlaams Instituut voor Biotechnologie (C0401, C0401)
- License Information
-
More Information
Article History
Received: 13 April 2023
Accepted: 4 September 2023
First Online: 30 September 2023
Declarations
:
: All autopsies were carried out according to local legislation with appropriate consent. Ethical approval for the use of cases was granted by the ethical committee of Ulm University (Germany, study 54/08) and UZ/KU-Leuven ethical committee (Belgium). This study covering the retrospective analysis of samples and data was approved by the UZ/KU-Leuven ethical committee (S-59295, S-65147, S-66705) (Belgium). The samples obtained from the UK were received from the brainbank donated for research by GE Healthcare after the phase III flutemetamol autopsy study had concluded [] (ClinicalTrials.gov identifiers NCT01165554, and NCT02090855).
: Not applicable for this study, which did not use person’s data. Only anonymized or pseudonymized data were processed.
: SOT received a BrightFocus Foundation postdoctoral grant. MO served as consultant for Axon neuroscience and Fujirebio and gave invited talks for Roche and Fujirebio. CAFvA received honoraria from serving on the scientific advisory board of Biogen, Roche, Novo Nordisk, MindAhead UG and Dr. Willmar Schwabe GmbH &Co. KG and has received funding for travel and speaker honoraria from Biogen, Roche diagnostics AG, Medical Tribune Verlagsgesellschaft mbH, Landesvereinigung für Gesundheit und Akademie für Sozialmedizin Niedersachsen e. V. and Dr. Willmar Schwabe GmbH &Co. KG and has received research support from Roche diagnostics AG. DRT received speaker honorary from Biogen (USA), travel reimbursement from UCB (Belgium) and collaborated with Novartis Pharma AG (Switzerland), Probiodrug (Germany), GE-Healthcare (UK), and Janssen Pharmaceutical Companies (Belgium). RV’s institution has a clinical trial agreement (RV as PI) with AviadoBio, Biogen, Denali, NovoNordisk, Prevail, Roche, UCB, Wave. RV’s institution has a consultancy agreement (RV as consultant) with ACImmune, Novartis, and Roche.Part of the samples studied here were received from the GE-Healthcare Flutemetamol Phase III trials (ClinicalTrials.gov identifiers NCT01165554, and NCT02090855) (GE-Healthcare, Amersham, UK).
